Intellectual disability and treatment-resistant epilepsy
Conditions
Interventions
Group 1: A retrospective analysis of all patients treated with cenobamate at the Séguin Clinic at the Kehl-Kork Epilepsy Center between 2020 and 2025, focusing on efficacy and tolerability.
Sponsors
Séguin-Klinik, Epilepsiezentrum Kork
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: All individuals over the age of 18 with treatment-resistant epilepsy who have been treated with cenobamate at the Séguin Clinic to date. Since cenobamate has been approved since 2021, data from the previous year will also be included in the analysis to ensure a comparison between the period before and after the medication was introduced. This results in the inclusion of data from the period between January 1, 2020, and December 31, 2025.
Exclusion criteria
Exclusion criteria: None.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recording of seizure frequency before the start of and during treatment with cenobamate, as well as side effects that occur during the course of treatment. Data collection is conducted retrospectively using routine data from clinical practice (particularly physician reports and laboratory results). | — |
Secondary
| Measure | Time frame |
|---|---|
| An assessment of the efficacy and tolerability of cenobamate based on seizure frequency and adverse effects in individuals with intellectual developmental disorders, with the aim of deriving clinically relevant guidance for its use (e.g., dosing or syndrome-specific application). | — |
Countries
Germany
Contacts
Public ContactPeter Martin
Séguin-Klinik, Epilepsiezentrum Kork
Outcome results
None listed